[Edaily Reporter Kim Seung-kwon] For medical artificial intelligence (AI) companies, the domestic market is viewed as a valuable testing ground and home turf for validating their technological capabilities. However, to achieve sustainable growth and significantly higher performance metrics, these companies must ultimately turn their attention to the massive U.S. market.

Medipixel, which has been targeting the global market since its inception, has now declared its leap toward becoming a global leader—going beyond mere overseas expansion to secure U.S. Current Procedural Terminology (CPT) codes, which are central to the U.S. insurance system, and transitioning to a platform that covers the entire treatment cycle.

“CPT Codes”: The Key to Entering the U.S. Market… A Head-On Breakthrough Through Partnerships

The success or failure of Medipixel’s vision for an era of 1000억 won in revenue hinges on its ability to establish a foothold in the U.S. market. However, the U.S. healthcare market presents high barriers for Korean companies to achieve success solely through their own sales networks, as regulations vary across the 50 states and the insurance system is complex. Recognizing the limitations of direct sales, Medipixel has chosen a strategic detour: joint development and collaboration with strategic partners who have a deep understanding of the local market ecosystem.

Currently, Medipixel is actively engaging in partnership discussions with a major U.S. company specializing in cardiovascular care that has already secured CPT (Current Procedural Terminology) codes and established a successful business model in the U.S. CPT codes are essential for billing insurance claims in the U.S. healthcare system, and collaborating with a partner that holds these codes is akin to paving a highway that allows Medipixel’s solutions to immediately penetrate U.S. hospital networks.

MediPixel plans to use this year’s double-digit growth—driven by its entry into the domestic non-insured market—as a springboard to achieve explosive revenue growth once insurance reimbursement in the U.S. becomes fully operational. Through this strategy, MediPixel aims to reach its internal break-even point (BEP) as early as 2028.

Song Gyo-seok, CEO of Medipixel, stated, “Entering the U.S. market and securing CPT codes are essential for us to leap forward into a company with sales in the 1000억 won range,” adding, “To this end, we are pursuing joint development and partnerships with companies that possess strong sales networks and expertise.”

Securing Financial Momentum Through a 10 Billion Won Series C Investment and an IPO

MediPixel is also making steady progress in securing the resources needed for global expansion. The market competitiveness MediPixel gained after its MPFFR was recently selected for a waiver from the New Medical Technology Evaluation process is drawing intense interest in the investment market. Leveraging this momentum, MediPixel is currently raising 10 billion won in Series C funding.

This funding round is expected to serve as more than just a means to secure working capital; it is likely to act as the final stepping stone toward U.S. clinical trials, strengthening partnerships, and an initial public offering (IPO). Based on its strengthened performance metrics, Medipixel has mapped out a concrete IPO roadmap to apply for a preliminary listing review between the end of next year and the beginning of the year after next. In line with the trend of increasingly stringent performance-based listing requirements, the company aims to secure a fair valuation by demonstrating tangible domestic and international revenue growth.

MediPixel’s ultimate goal is not merely to be a company that sells individual diagnostic assistance software. Currently equipped with two key tools—MPXA, which aids in morphological diagnosis, and MPFFR, which performs functional diagnosis—MediPixel aspires to evolve into an intelligent platform company that manages the entire process of cardiovascular interventional procedures by integrating these into a single platform.

The vision they have named is “Continuous Intelligence.” The goal is to connect the previously fragmented procedural cycle—from the pre-procedure diagnostic stage, through procedure planning and guidance during the actual procedure, to post-procedure result verification—into a single, seamless data flow. Through this, AI will transcend its role as a mere辅助 tool to become an “intelligence augmentation” that predicts patients’ long-term risk and maximizes physicians’ decision-making capabilities.

CEO Song emphasized, “Medipixel’s ultimate goal is to evolve beyond individual products into a Continuous Intelligence platform that provides physicians with uninterrupted insights throughout the entire procedure,” adding, “Through this, we will emerge as the world’s leading AI company in cardiovascular interventional procedures.”